Single-Inhaler Triple vs Long-Acting Beta2-Agonist-Inhaled Corticosteroid Therapy for COPD

2024/10/24 by Samy Suissa, Sophie Dell’Aniello, Sophie Dell'Aniello +1 · 1 voice · 1 citation
Medicine · #Asthma and respiratory diseases #Chronic Obstructive Pulmonary Disease (COPD) Research #Inhalation and Respiratory Drug Delivery

paper · doi:10.1016/j.chest.2024.10.025

openalex publication_date 2024/10/24 · crossref created 2024/10/24 · openalex created_date 2024/10/25 · crossref issued 2025/03/01 · crossref published 2025/03/01 · crossref published-print 2025/03/01 · crossref deposited 2026/05/13 · crossref indexed 2026/05/13 · openalex updated_date 2026/08/02

Citations

• Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019
• Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum

Cited by

• The Bronchodilator and Anti‐Inflammatory Effect of Long‐Acting Muscarinic Antagonists in Asthma: An EAACI Position Paper

Discussions

• Does single-inhaler triple therapy increase the incidence of major adverse cardiovascular events compared with LABA-ICS? Read the full research in the March issue of the journal CHEST®: doi.org/10.101 [bsky, 1 points, 0 comments]